EVX B3
Alternative Names: EVX-B3Latest Information Update: 12 Dec 2024
Price :
$50 *
At a glance
- Originator Evaxion Biotech
- Class Bacterial vaccines; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Respiratory tract infections
Most Recent Events
- 09 Dec 2024 Preclinical development is ongoing in Denmark
- 28 Oct 2024 No recent reports of development identified for preclinical development in Respiratory-tract-infections(Prevention) in Denmark
- 18 Sep 2023 Evaxion Biotech and MSD agree to co-develop EVX B3 for Respiratory tract infection(Prevention)